Telegram RegisterThe public register of Telegram

Channel

미래에셋 제약/바이오 김승민

@bioksm

On this record: Also posting the same content · Growth · Engagement · What this channel posts · Posts · Posts edited after publishing · Citations · Cite this entry

14,740subscribers

-8 since we began measuring on 6 August 2026

Risers and fallers across the register · movement among entries of 10,000–31,623.

Register entry

Telegram ID-1001371973147
TypeChannel
Username@bioksm
Description한국/미국/중국 바이오 업종에 대한 발간 자료와 의견 공유.
Created2 June 2021measured — cross-checked against a third-party dataset (ext.tg_channel)
First recorded6 August 2026
Last confirmed live13 August 2026
Measurements held8
Confirmed unchanged1 time, most recently 13 August 2026
On Telegramt.me/bioksm

Also posting the same content

This channel’s posts match, word for word or near enough, posts on 1 other registered channel, found by comparing text fingerprints across every channel on the register. That matching has been checked by hand against the live Telegram pages and found reliable — 0 wrong of 45 pairs re-read.

Which channel, if either, published first is deliberately not shown. The same hand-check found that reading wrong 18 of 45 times — 60%, no better than a coin flip — because it depends on how deep our own crawl happened to reach into each channel’s history, not on when the content was actually first posted. This list is ordered by subscriber count, the same as every other listing on this site, never by which channel we think came first. Word-for-word matching has several ordinary explanations besides copying — a channel mirroring itself, an unattributed repost, or two channels independently repeating the same wire story — and this measurement cannot tell those apart. How this is measured.

Growth

14,74014,75314,746.56 August 2026 — 14,748 subscribers7 August 2026 — 14,752 subscribers8 August 2026 — 14,748 subscribers9 August 2026 — 14,747 subscribers10 August 2026 — 14,746 subscribers11 August 2026 — 14,753 subscribers12 August 2026 — 14,748 subscribers13 August 2026 — 14,740 subscribers6 August 202613 August 2026
8 measurements spanning 7 days, net -8. Dots are measurements; the straight line between them is drawn to join them, not to claim we know the path taken in between — snapshots are recorded only when a count changes, so gaps mean “no change observed”, never “interpolated”. The vertical axis spans 14,738–14,755 and does not start at zero.
Measurement log — every subscribers count we have recorded
Measured (UTC)SubscribersChange
13 Aug 2026, 02:2614,740-8
12 Aug 2026, 04:1514,748-5
11 Aug 2026, 05:1514,753+7
10 Aug 2026, 03:1114,746-1
9 Aug 2026, 05:0314,747-1
8 Aug 2026, 04:1314,748-4
7 Aug 2026, 04:2814,752+4
6 Aug 2026, 04:4914,748first reading

Engagement

36 posts held, back to 31 July 2026the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 18 pagesof Telegram’s post history, 20 posts per page.

ERR · 30 days
29.2%
avg views ÷ 14,740 subscribers
Avg views / post
4,310
35 posts measured
Reaction rate
this channel exposes no reaction counts
Posts in window
36
of 36 held

ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.

ER is defined industry-wide as (forwards + reactions + comments) ÷ views— note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.

What these figures were computed from
WindowRolling 30 days · latest post in window 12 August 2026
Posts held36 (31 July 202612 August 2026)
Views total150,786
Reactions total
Forwards / commentsnot exposed by the public surface — not measured, not estimated
Readings taken13 Aug 2026, 16:17 UTC

Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.

Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.

Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.

What this channel posts

Photos
1,190
Links
2,720

Lifetime counters from Telegram’s own channel header, read 13 August 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.

Recent posts

12 Aug 2026, 23:18 UTC≈1,740 viewsread 13 August 2026

[미래에셋 제약/바이오 김승민] 8/13 Daily https://t.me/bioksm 🌍 글로벌 바이오/제약 ──────────────────── ▶️ 릴리, 비만치료제 레타트루타이드 불법 판매 관련 6개사 상대 소송 제기 ▶️ 아케소의 이보네시맙, 중국서 1차 치료 NSCLC 획기적 승인 획득 ▶️ 디피니움, 불안증 치료 사이케델릭 약물 3상에서 긍정 결과 🇰🇷 한국 바이오/제약 ──────────────────── ▶️ 상업화 바이오텍으로 진화한 알테오젠, 올해 네 번째 기술수출 터질까? ▶️ 올릭스 “CPS 전환 물량, 즉시 시장 출회되는 구조 아냐” ▶️ 엘앤씨바이오, 1406억 규모 유증 앞두고 최대주주·FI 지분 매각 ▶️ 아이진-한국비엠아이, ‘유전자 재조합 톡신’ 식약처 수출용 허가 신청

12 Aug 2026, 06:59 UTC696 viewsread 13 August 2026
Forwarded from @olix_official

안녕하세요, 올릭스 커뮤니케이션실입니다. 금일 주가 변동으로 인해 많이 걱정하고 계실 주주 여러분의 마음을 잘 알고 있습니다. 특히 지난해 발행한 CPS의 보통주 전환 가능 시점이 다가오면서, 관련 물량이 단기간에 시장에 출회되는 것 아니냐는 우려가 있으신 것으로 파악하고 있습니다. 이에 현재 상황을 주주 여러분께 직접 설명드리고자 합니다. ■ CPS 전환 가능 시점 관련 해당 CPS의 보통주 전환청구 가능 개시일은 8월 29일이나, 해당일이 토요일인 관계로 실제 전환청구가 가능한 첫 영업일은 8월 31일입니다. 전환청구가 이루어진다고 하더라도 실제 보통주가 상장되어 거래 가능해지기까지는 일정 기간이 소요됩니다. 따라서 전환 가능 물량 전체가 8월 31일부터 즉시 시장에 출회되는 구조는 아닙니다. ■ 기존 CPS 투자자 관련 당시 투자

11 Aug 2026, 22:09 UTC≈2,410 viewsread 13 August 2026

[미래에셋 제약/바이오 김승민] 8/12 Daily https://t.me/bioksm 🌍 글로벌 바이오/제약 ──────────────────── ▶️ Zydus Sentynl, Mereo의 3상 준비 단계 희귀 유전성 폐질환 치료제 $475mn에 인수 ▶️ 트럼프 대통령, 소아 백신 권고사항 개편 행정명령 서명 ▶️ WuXi AppTec, 미 국방부 중국 군수업체 브랜드 관련 분쟁속 일시적 승리 ▶️ Scholar Rock, SMA 치료제 FDA 재제출을 과정에서 노보의 Catalent 시설 제외 ▶️ 바데리스, 희귀 혈관질환 3상 임상시험 진행 위해 1억 5,200만 달러 펀딩 확보 🇰🇷 한국 바이오/제약 ──────────────────── ▶️ 국내 제약바이오 ‘매출 1조 클럽’ 확대…동국제약·SK바이오팜 합류 주목

10 Aug 2026, 22:16 UTC≈2,510 viewsread 13 August 2026

[미래에셋 제약/바이오 김승민] 8/11 Daily https://t.me/bioksm 🌍 글로벌 바이오/제약 ──────────────────── ▶️ Lilly의 체중감량알약 Foundayo, 영국에서 유럽 첫 승인 확보 ▶️ BeOne Medicines와 Revolution Medicines는 임상 개발 및 지역별 상용화를 위한 협력 ▶️ Novo Nordisk, 아마존과 AI 활용 신약개발 가속화 파트너십 체결 ▶️ Jazz, 간질 치료제 포트폴리오 확대 위해 Actio Biosciences 업프론트 $820mn에 인수 ▶️ Teledyne, Varex Imaging을 $1.1bn에 인수 ▶️ BMS, 휴스턴에 23억 달러 규모 제조 시설 건설 계획 발표 ▶️ AbCellera, 혈관 운동성 증상 개선제 '놀라운' 임상

10 Aug 2026, 08:49 UTC≈1,660 viewsread 13 August 2026
Forwarded from @miraeelecPhoto

[미래에셋증권 장다현] 글로벌 AI 인프라 (비중확대/신규) : AI도 결국 연결빨 *보고서 링크: https://han.gl/3q7Pw AI 데이터센터는 GPU만으로 완성되지 않습니다. 수천 개의 가속기를 하나의 시스템처럼 묶으려면 NIC, 스위치, AEC, 광모듈이 필요합니다. 네트워크는 원가 비중은 작지만, 병목이 생기면 가장 비싼 GPU의 가동률을 떨어뜨립니다. AI도 결국 연결이 중요한 이유입니다. 이번 보고서에서는 Big 5의 공시 CapEx가 놓치는 투자까지 포착하기 위해 캠퍼스 106곳과 클라우드 리전 121곳을 추적했습니다. 그 결과 IT 전력은 2025~2028년 3.1배, 주요 네트워크 기업의 AI 매출은 5.9배 증가할 전망입니다. 2027년은 ‘AI도 결국 연결빨’이라는 투자 논리가 실적으로 증명될 해입니다.

10 Aug 2026, 07:40 UTC≈1,270 viewsread 13 August 2026
Forwarded from @darthacking

2026.08.10 16:38:11 기업명: 유한양행(시가총액: 6조 5,311억) A000100 보고서명: 주식등의대량보유상황보고서(약식) 대표보고 : 블랙록 펀드 어드바이저스/미국 보유목적 : 단순투자 보고전 : 5.07% 보고후 : 6.50% 보고사유 : - 단순투자목적으로 장내에서 발행회사의 주식 매수 * BlackRock (Singapore) Limited 2026-07-13/장내매수(+)/보통주/ 28주/- 2026-07-22/장내매수(+)/보통주/ 260주/- * BlackRock Advisors (UK) Limited 2026-07-27/장내매수(+)/보통주/ 455주/- 2026-07-28/장내매수(+)/보통주/ 455주/- 2026-07-29/장내매수(+)/보통주/ 8주/- 2026-07-30/장내매수(+)/보통주/

10 Aug 2026, 07:40 UTC≈1,110 viewsread 13 August 2026
Forwarded from @darthacking

2026.08.07 17:30:39 기업명: 알테오젠(시가총액: 16조 3,438억) A196170 보고서명: 주식등의대량보유상황보고서(약식) 대표보고 : 블랙록 펀드 어드바이저스/미국 보유목적 : 단순투자 보고전 : -% 보고후 : 5.03% 보고사유 : - 단순투자목적으로 장내에서 발행회사의 주식 매수 * BlackRock(Netherlands) B.V. 2026-07-30/신규보고(+)/보통주/ 13,438주/5% 미만/주) * BlackRock(Singapore) Limited 2026-07-30/신규보고(+)/보통주/ 3,880주/5% 미만/주) * BlackRockAdvisors (UK)Limited 2026-07-30/신규보고(+)/보통주/ 431,361주/5% 미만/주) 2026-07-31/장내매수(+)/보통주/ 399

10 Aug 2026, 05:53 UTC≈1,790 viewsread 13 August 2026
Forwarded from @qooowooo

[코스닥 Bi-Weekly] 승강재 미리보기∥미래에셋증권 윤재홍 ▼[자료 링크] https://han.gl/bkySx ▼ 코스닥 Level-UP의 시그널(6/1) https://han.gl/gSPOD 하반기 전망 자료 '코스닥 Level-UP의 시그널'의 두 번째 업데이트 자료입니다. 이번 자료에서는 코스닥 승강제 관련 내용과 함께 시장 모니터링 내용을 정리했습니다. - 9~10월 기준안 발표 이후 내년 초 도입 예정(기존 10월 도입) - 정책 방향이 '대형우량주'에 집중되어 있는 만큼 수급 효과도 기대 - 정책 발표 내용 및 기존 지수 방법론을 고려하면 시가총액 기준에 '영업이익, 자기자본이익률(ROE)' 등이 후보로 거론될 수 있어 자세한 내용은 보고서를 참고해주세요. 감사합니다.

10 Aug 2026, 00:38 UTC≈14,700 viewsread 13 August 2026
Photo

XBI vs. 코스닥 바이오 코로나 이후 흐름과 괴리

10 Aug 2026, 00:37 UTC≈19,400 viewsread 13 August 2026
Photo

XBI vs. 코스닥 바이오 10년 흐름과 괴리

9 Aug 2026, 21:44 UTC≈2,830 viewsread 13 August 2026

[미래에셋 제약/바이오 김승민] 8/10 Daily https://t.me/bioksm 🌍 글로벌 바이오/제약 ──────────────────── ▶️ Biotech Investment National Security Act(BINSA), 중국 바이오 기업 거래에 대한 심사를 강화해야한다는 압박 ▶️ FDA 패널, Grail의 혈액 기반 암 검사 검토 예정 ▶️ Biomarin, 3상 말기 임상 실패로 $270mn 규모 희귀질환 치료제 중단 ▶️ 아마존 약국은 메디케어 브리지 프로그램을 통해 GLP-1 제제를 월 50달러에 제공 🇰🇷 한국 바이오/제약 ──────────────────── ▶️ 리가켐, 美 넥스트큐어서 ADC 'LNCB74' 단독 권리 확보 ▶️ 알테오젠 '기술료’에 2Q 실적도 쭉, 전년비 269% 늘어

Showing the 12 most recent of 36 posts we hold for @bioksm. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.

Posts edited after publishing

@bioksm edited 1 post after it first published — the same permalink now carries different wording than the one this register originally read, caught because our own crawl held a copy of the earlier text.

An edit is not deception. Typo fixes, price updates and corrections look exactly like this too — this register can tell you the wording changed and when, not why. How this is measured.

First edit seen
10 August 2026
Most recent edit
10 August 2026

Citation-graph rank

Citation-graph rank — 237,935 of 1,176,251entries in the measured graph. A weighted position computed from the forward and mention edges below — republished posts weigh more than named mentions — and recomputed periodically, over the whole graph. Published only as this ordinal position, never as a score: a position is a fact, and a score printed beside one channel’s name would read as a verdict this register does not make. The two counts beneath stay separate for the same reason mentions are never summed with forwards anywhere else on this page — a named-by count costs nothing to manufacture. The top 100 by this measure, or how it is computed.

Forward network

Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.

Mentions

Named by 2 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.

Names

Channels on the register whose handles appear in this channel's posts.

A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.

Cite this entry

A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 13 August 2026 — this entry's latest reading, not the date you are reading this.

“미래에셋 제약/바이오 김승민” (@bioksm), 14,740 subscribers as measured 13 August 2026. Telegram Register, tgregister.com/channel/bioksm.

Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.